Real-world outcomes of chemo-antiangiogenesis versus chemo-immunotherapy combinations in EGFR-mutant advanced non-small cell lung cancer patients after failure of EGFR-TKI therapy

BACKGROUND: Despite the potent efficacy of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) in the treatment of EGFR-mutant non-small cell lung cancer (NSCLC) patients, drug resistance inevitably ensues, and there remains a paucity of treatment options in clinical practice....

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Xin, Li, Jiaqi, Ye, Lingyun, Zhao, Jing, Xie, Mengqing, Zhou, Juan, Shen, Yinchen, Zhou, Fei, Wu, Yan, Han, Chaonan, Qian, Jialin, Chu, Tianqing, Su, Chunxia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8512457/
https://www.ncbi.nlm.nih.gov/pubmed/34733628
http://dx.doi.org/10.21037/tlcr-21-681

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8512457/
https://www.ncbi.nlm.nih.gov/pubmed/34733628
http://dx.doi.org/10.21037/tlcr-21-681

Ejemplares similares